Long-term stability of the triglyceride-glucose index in cancer patient Cohort
Abstract
The triglyceride-glucose (TyG) index is a simple surrogate marker for insulin resistance (IR), but its longitudinal stability and clinical predictive value in patients with cancer remain poorly understood. To evaluate whether cancer and anti-tumor therapies affect the longitudinal stability of the TyG index over 24 months and to identify its core influencing factors. This retrospective study analyzed 538 cancer patients from a single-center database (2015-2020) who completed five TyG index measurements over 24 months. Longitudinal stability was quantified using repeated measures analysis of variance (RM-ANOVA) and intraclass correlation coefficients (ICC). Binary logistic regression models were employed to explore factors associated with different TyG levels. A longitudinal K-means clustering algorithm was used to identify trajectory differences, and multivariable logistic regression models determined the independent predictive factors. The TyG index demonstrated excellent longitudinal stability over 24 months (F = 5.38, P 8.79). K-means clustering identified three parallel longitudinal trajectories (Stable-Low, Stable-Medium, and Stable-High risk). Multivariable logistic regression models indicated that the high-risk trajectory was significantly associated with BMI (OR = 1.25, 95% CI 1.10-1.41, P < 0.001) and diabetes mellitus, whereas advanced cancer stage (OR = 0.95, 95% CI 0.53-1.70, P = 0.862) and cachexia (OR = 0.90, 95% CI 0.45-1.80, P = 0.767) showed no significant…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 538 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.